EXACT Sciences Corporation Release: 88% Sensitivity Reported For Stool DNA Colorectal Cancer Screening Technology In Abstract Presented At 2006 DDW Conference

LOS ANGELES--(BUSINESS WIRE)--May 22, 2006--EXACT Sciences Corporation (NASDAQ: EXAS - News) announced today that the results of a research study on next generation stool DNA testing technology were presented at the annual Digestive Disease Week (DDW) conference, the world's largest meeting of gastroenterology professionals. Using a simplified panel of markers and a new buffer and DNA capture technology, EXACT's stool DNA technology demonstrated an 88% sensitivity for cancer, with a specificity of 82%. The data were presented on Sunday, May 21st at the Los Angeles Convention Center.